title: NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
abstract: The use of positron emission tomography (PET) is increasing rapidly in the United States, with the most common use of PET scanning related to oncology. It is especially useful in the staging and management of lymphoma, lung cancer, and colorectal cancer, according to a panel of expert radiologists, surgeons, radiation oncologists, nuclear medicine physicians, medical oncologists, and general internists convened in November 2006 by the National Comprehensive Cancer Network. The Task Force was charged with reviewing existing data and developing clinical recommendations for the use of PET scans in the evaluation and management of breast cancer, colon cancer, non-small cell lung cancer, and lymphoma. This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology.
authors.forename: Donald A
authors.initials: DA
authors.lastname: Podoloff
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: Craig
authors.initials: C
authors.lastname: Allred
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Brown
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
authors.forename: Robert W
authors.initials: RW
authors.lastname: Carlson
authors.forename: R Edward
authors.initials: RE
authors.lastname: Coleman
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Dominique
authors.initials: D
authors.lastname: Delbeke
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Edge
authors.forename: David S
authors.initials: DS
authors.lastname: Ettinger
authors.forename: Frederic W
authors.initials: FW
authors.lastname: Grannis
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Hillner
authors.forename: John M
authors.initials: JM
authors.lastname: Hoffman
authors.forename: Krystyna
authors.initials: K
authors.lastname: Kiel
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Komaki
authors.forename: Steven M
authors.initials: SM
authors.lastname: Larson
authors.forename: David A
authors.initials: DA
authors.lastname: Mankoff
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Rosenzweig
authors.forename: John M
authors.initials: JM
authors.lastname: Skibber
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.forename: Jq Michael
authors.initials: JM
authors.lastname: Yu
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000628:therapy; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000628:therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D009369:Neoplasms / Q000175:diagnosis*; D049268:Positron-Emission Tomography; D011379:Prognosis; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18